8-K: The Joint Corp. Reports Mixed Q2 Results Amid Refranchising Efforts

The Joint Corp. announced a 3% revenue increase and a net loss of $3.6 million for the second quarter of 2024, as it continues its refranchising strategy.

Summary

• The Joint Corp. reported a 3% increase in revenue to $30.3 million for the second quarter of 2024 compared to $29.3 million in the same period last year.
• The company experienced a net loss of $3.6 million, which includes $1.5 million in litigation expenses and $1.4 million in losses on disposition or impairment of assets.
• Adjusted EBITDA was $2.1 million, down from $3.2 million in the second quarter of 2023.
• System-wide sales increased by 8% to $129.6 million, while system-wide comparable sales grew by 2%.
• The total clinic count reached 960, with 829 franchised and 131 company-owned or managed clinics.
• The company sold 7 franchise licenses in the quarter, compared to 21 in the prior year, reflecting the impact of the refranchising process.
• For the first half of 2024, revenue was $60.0 million, compared to $57.6 million in the first half of 2023, and the net loss was $2.6 million.
• The company has $17.5 million in unrestricted cash as of June 30, 2024, compared to $18.2 million at the end of 2023.
• The company reiterated its 2024 guidance, expecting system-wide sales between $530 and $545 million and mid-single-digit growth in system-wide comp sales.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there is revenue growth and a positive outlook, the net loss, decreased EBITDA, and increased expenses temper the positive aspects. The refranchising strategy is a positive move, but the results are mixed.

Positives

• Revenue increased by 3% in Q2 2024 compared to Q2 2023.
• System-wide sales saw an 8% increase in Q2 2024.
• The company has a strong liquidity position with $17.5 million in unrestricted cash and access to a $20 million line of credit.
• The company is making progress in refranchising corporate clinics with multiple letters of intent in place.
• The company is focused on improving unit economics and clinic profitability through innovation in operations, IT, and marketing.
• The company has a large and growing market with a recurring revenue model.

Negatives

• The company reported a net loss of $3.6 million in Q2 2024, compared to a net loss of $320,000 in Q2 2023.
• Adjusted EBITDA decreased to $2.1 million in Q2 2024 from $3.2 million in Q2 2023.
• The company experienced a $1.4 million loss on disposition or impairment of assets.
• General and administrative expenses increased to $22.6 million, primarily due to $1.5 million in legal expenses.
• Franchise license sales decreased to 7 in Q2 2024 from 21 in Q2 2023, reflecting the refranchising process.
• Depreciation and amortization expenses decreased 35% due to the impact of corporate clinics being held for sale.

Risks

• The company faces challenges in identifying and recruiting qualified chiropractors and other personnel due to a nationwide labor shortage.
• Inflation has increased the company's costs and could negatively impact the business.
• The company may fail to profitably operate company-owned or managed clinics.
• The company may fail to refranchise as planned.
• Short-selling strategies and negative opinions posted online could drive down the stock price and result in class action lawsuits.
• The company may fail to remediate future material weaknesses in internal control over financial reporting.
• The company is exposed to risks related to outbreaks of contagious diseases.

Future Outlook

The company reiterated its 2024 guidance, expecting system-wide sales between $530 and $545 million, mid-single-digit growth in system-wide comp sales, and 60 to 75 new franchised clinic openings, excluding refranchised clinics.

Management Comments

• Peter D. Holt, President and Chief Executive Officer, stated that the company delivered topline growth and positive Adjusted EBITDA in the second quarter, despite ongoing economic concerns.
• Management believes that system-wide sales information is important in understanding the company's financial performance because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base.

Industry Context

The Joint Corp. operates in the chiropractic care industry, which is a growing market with a significant out-of-pocket spend. The company's refranchising strategy and focus on unit economics are aimed at improving its competitive position and profitability within this market.

Comparison to Industry Standards

• The Joint Corp.'s system-wide sales growth of 8% is a positive indicator, but the decrease in Adjusted EBITDA and the net loss raise concerns about profitability compared to industry benchmarks.
• Companies like Massage Envy and other franchised healthcare providers may serve as benchmarks for comparison, but specific financial details would be needed to make a direct comparison.
• The company's focus on refranchising is a strategy that other franchise businesses have used to improve profitability and reduce corporate overhead.
• The company's growth in clinic count to 960 locations is a significant achievement, but the number of new franchise licenses sold has decreased, which may be a concern for future growth.

Legal Proceedings

• The company incurred $1.5 million in legal expenses related to a class action suit regarding time and wages in California.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decreased EBITDA.
• Franchisees may benefit from the refranchising efforts and increased support from the company.
• Employees may be impacted by the ongoing labor shortage and potential changes in operations.
• Customers may benefit from the company's focus on improving access to chiropractic care.

Next Steps

• The company plans to aggressively market clusters of clinics for refranchising.
• The company will continue to focus on improving unit economics and clinic profitability.
• The company will host a conference call to discuss the results on August 8, 2024.

Key Dates

Keywords

chiropractic, franchise, refranchising, EBITDA, system-wide sales, clinic, revenue, net loss, healthcare